Edesa Biotech, Inc. (EDSA)

Over the past six months, Edesa Biotech's stock price has been significantly impacted by several clinical trial developments and financial reports. On February 24, 2026, shares surged 77% after positive results from a Phase 3 study of paridiprubart (EB05). On December 12, 2025, the stock declined 16.09% following the company's report of its Fiscal Year 2025 results. On February 13, 2026, the stock showed a slight increase of 0.49% after Edesa Biotech reported its Fiscal 1st Quarter 2026 results. On March 26, 2026, the stock decreased by 10.81% after Edesa Biotech announced it was advancing its vitiligo program. On March 31, 2026, Edesa Biotech was invited for an oral showcase at the Respiratory Innovation Summit, leading to a 6.12% increase in stock price. As of May 8, 2026, the company's stock price was $16.30 per share, representing a significant increase of 691.26% from May 9, 2025.

Information regarding specific demand seasonality for Edesa Biotech's products and services is not explicitly detailed. As a clinical-stage biopharmaceutical company, its revenue generation is primarily tied to the successful development and commercialization of its drug candidates, rather than seasonal consumer demand for existing products. The demand for its pipeline products, once commercialized, would likely be driven by disease prevalence and treatment efficacy rather than seasonal patterns.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, manufacturing, and commercializing pharmaceutical products for inflammatory and immune-related diseases. The company's major product candidates include EB05 (paridiprubart) for ARDS, EB01 (1.0% daniluromer cream) for chronic Allergic Contact Dermatitis, EB06 for vitiligo, and EB07 for systemic sclerosis and pulmonary fibrosis. Edesa Biotech also holds a license agreement with NovImmune SA for TLR4 and CXCL10 antibodies and a collaboration agreement with Yissum Research Development Company for topical dermal and anorectal applications.

Edesa Biotech, Inc. is headquartered in Markham, Ontario, Canada.

Edesa Biotech's reputation is primarily influenced by its clinical trial progress and scientific presentations. Positive results from its Phase 3 study of paridiprubart and engagement with industry leaders at events like the Global Vitiligo Foundation Annual Scientific Symposium enhance its standing. The company's invitation to oral showcases at events like the Respiratory Innovation Summit indicates recognition within its field. There is no specific information found regarding negative events that have affected Edesa Biotech's brand reputation in the past year, beyond the general risks associated with clinical-stage biopharmaceutical companies.

The ownership structure of Edesa Biotech (EDSA) stock is a mix of institutional, insider, and public/individual investors. Approximately 0.86% to 5.50% of the company's stock is owned by institutional investors. Insiders hold about 17.76% of the stock, while public companies and individual investors own approximately 80.41%. Major institutional owners and shareholders include Rubric Capital Management LP, Stonepine Capital Management, LLC, and Velan Capital Investment Management LP, among others. Pardeep Nijhawan, the CEO, owns a significant number of shares.